Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Aug 16, 2011

Premium

Agilent Technologies this week launched its SureScan Microarray Scanner, which is configured to image its million-feature SurePrint microarrays.

The instrument has also been certified in accordance with the International Organization for Standards 13485 document, which governs the design and manufacture of medical devices.

Agilent claims that the SureScan system allows users to continuously load microarray slides while the instrument is operating. With the system's random scanning capability, customers can also reprioritize and rearrange the scan queue order at any point during the operation, the company said.

The system also combines a newly designed slide cover and a built-in ozone barrier system to minimize dye signal degradation. A dynamic autofocus mechanism in conjunction with a detection limit of as low as 0.01 fluorophores per square micron allows users to capture quality data from samples with both low and high signals, Agilent claimed.

Following scanning, raw image data is automatically loaded into Agilent's Feature Extraction software, eliminating manual transfer, the firm added.


DNA Diagnostics Center a Fairfield, Conn.-based provider of private DNA paternity and other DNA tests, announced the availability of its SNP microarray-based DDC Non-Invasive Prenatal Paternity Test.

The test is run as a service in DDC's Clinical Laboratory Improvement Amendments-compliant laboratory. Results are generated from blood samples from the mother and alleged father, the firm added.

Michael Baird, chief science officer of DDC, said in a statement that the test "provides an alternative for people seeking paternity results prior to the baby's birth," and said it could "replace paternity tests that utilize procedures such as amniocentesis, which are invasive and carry risks for the mother and the child."

DDC's was able to launch the test after obtaining an exclusive license from Gene Security Network, a privately held genetic company.